The French cosmetics giant is unveiling some details about Melasyl, its new multi-patented molecule designed to address localized pigmentation issues that lead to age spots and post-acne marks.
Already available in La Roche Posay’s Mela B3 franchise, including MelaB3 serum and MelaB3 SPF30, the new ingredient helps provide a more even, natural skin tone, addressing even the most persistent marks across all skin tones, claims L’Oréal.
According to a landmark, worldwide epidemiological study on pigmentary disorders, half of all people report having at least one skin pigmentation issue [1].
“With half of all people reporting skin pigmentation issues and a third of these experiencing lower quality of life as a result, the impact of visible spots or post-acne marks is clearly more than skin-deep,” said Anne Colonna, Global Head of Advanced Research at L’Oréal Groupe. “Melasyl is a first-of-its kind ingredient that helps to address localized skin pigmentation issues, with proven efficacy and wide accessibility that will enable more people to regain their self confidence.”
The L’Oréal group said its L’Oréal Paris and Vichy brands will follow with future product launches, expanding consumer access to expert formulations containing the new ingredient.
Melasyl was first presented at the World Congress of Dermatology 2023 in Singapore, alongside the first worldwide epidemiological study on pigmentary disorders. Melasyl was recently featured at the American Academy of Dermatology’s annual meeting in San Diego from March 8-12, 2024.
